Xilio Therapeutics Q3 revenue falls to $10.0 million; net loss narrows to $5.9 million
Xilio Therapeutics reported third quarter 2026 results for the period ended September 30, 2026. Collaboration and license revenue fell to $10.0 million from $19.1 million a year earlier, while the net loss narrowed to $5.9 million from $16.3 million, mainly because of a non-cash warrant fair value gain, and operating loss widened. The company says its cash will fund operations into the first quarter of 2028, excluding up to $36.2 million in possible Series C warrant proceeds.
Key points
- Collaboration and license revenue was $10.0 million, down from $19.1 million in Q3 2025, driven by lower revenue under the AbbVie and Gilead agreements.
- Net loss was $5.9 million, or $(0.30) per share, versus $16.3 million, or $(1.58) per share, a year earlier; the change in fair value of warrant liabilities was a $4.8 million gain versus a $15.4 million loss.
- Loss from operations was $11.7 million versus $1.9 million a year earlier, as R&D expenses rose to $14.8 million and G&A expenses to $6.9 million.
- Cash and cash equivalents were $122.2 million at September 30, 2026, with runway stated into the first quarter of 2028.
The filing
Written by AI on Nov 10, 2026, 7:45 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.